文献速递血栓与止血

A型血友病小鼠中TAFI激活缺陷是关节出血的主要原因

Defective TAFI activation in hemophilia A mice is a major contributor to joint bleeding.
PubMed 文献 · Blood · 2018-07-19

研究比较了获得性A型血友病(aHA)野生型小鼠与先天性A型血友病(FVIII-/-)小鼠在关节损伤和断尾后的出血表型,发现aHA小鼠关节出血明显轻于FVIII-/-小鼠,而断尾出血两者均严重。机制上FVIII-/-小鼠关节损伤后TAFI激活严重缺陷,aHA小鼠则存在明显TAFI激活;TAFI缺失使aHA小鼠关节出血增至与FVIII-/-小鼠无法区分。uPA介导的纤溶驱动关节出血,tPA介导的纤溶参与断尾出血。

要点

  • aHA与FVIII-/-小鼠断尾后均严重出血,但aHA关节出血明显轻于FVIII-/-小鼠。
  • FVIII-/-小鼠关节损伤后TAFI激活严重缺陷,aHA小鼠存在明显TAFI激活。
  • uPA介导的纤溶驱动关节出血,tPA介导的纤溶参与断尾出血。

核心结论

  • TAFI通过抑制uPA介导的纤溶成为aHA关节出血的重要修饰因子。
  • 先天性FVIII-/-小鼠因TAFI激活严重缺陷而缺乏TAFI的出血保护作用。
  • 考虑血友病关节出血的促止血策略时,除血凝块形成外还需重视血凝块保护。

研究设计与样本

  • 在aHA野生型(WT)小鼠(接受抗FVIII抗体)与先天性HA(FVIII-/-)小鼠中比较关节损伤和断尾后的出血表型。
  • 使用TAFI-/-小鼠联合抗FVIII抗体观察关节出血。
  • 检测关节损伤后循环TAFI酶原消耗以评估体内TAFI激活。
  • 使用纤溶药理学抑制剂区分uPA与tPA介导的纤溶对关节出血和断尾出血的作用。

主要发现

  • aHA与FVIII-/-小鼠断尾后均出血严重,但关节出血aHA较FVIII-/-小鼠明显更轻。
  • TAFI-/-小鼠联合抗FVIII抗体的关节出血较WT aHA小鼠增加,并与FVIII-/-小鼠关节出血无法区分。
  • 关节损伤后循环TAFI酶原消耗测定显示FVIII-/-小鼠体内TAFI激活严重缺陷,而aHA小鼠可见明显TAFI激活。
  • uPA诱导的纤溶驱动关节出血,tPA介导的纤溶参与断尾出血。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Joint bleeds are common in congenital hemophilia but rare in acquired hemophilia A (aHA) for reasons unknown. To identify key mechanisms responsible for joint-specific bleeding in congenital hemophilia, bleeding phenotypes after joint injury and tail transection were compared in aHA wild-type (WT) mice (receiving an anti-factor VIII [FVIII] antibody) and congenital HA (FVIII-/-) mice. Both aHA and FVIII-/- mice bled severely after tail transection, but consistent with clinical findings, joint bleeding was notably milder in aHA compared with FVIII-/- mice. Focus was directed to thrombin-activatable fibrinolysis inhibitor (TAFI) to determine its potentially protective effect on joint bleeding in aHA. Joint bleeding in TAFI-/- mice with anti-FVIII antibody was increased, compared with WT aHA mice, and became indistinguishable from joint bleeding in FVIII-/- mice. Measurements of circulating TAFI zymogen consumption after joint injury indicated severely defective TAFI activation in FVIII-/- mice in vivo, consistent with previous in vitro analyses in FVIII-deficient plasma. In contrast, notable TAFI activation was observed in aHA mice, suggesting that TAFI protected aHA joints against bleeding. Pharmacological inhibitors of fibrinolysis revealed that urokinase-type plasminogen activator (uPA)-induced fibrinolysis drove joint bleeding, whereas tissue-type plasminogen activator-mediated fibrinolysis contributed to tail bleeding. These data identify TAFI as an important modifier of hemophilic joint bleeding in aHA by inhibiting uPA-mediated fibrinolysis. Moreover, our data suggest that bleed protection by TAFI was absent in congenital FVIII-/- mice because of severely defective TAFI activation, underscoring the importance of clot protection in addition to clot formation when considering prohemostatic strategies for hemophilic joint bleeding.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Wyseure T, Cooke EJ, Declerck PJ, et al. Defective TAFI activation in hemophilia A mice is a major contributor to joint bleeding. Blood. 2018. PMID: 30026184. doi:10.1182/blood-2018-01-828434

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。